XERIS BIOPHARMA HOLDINGS INC's ticker is and the CUSIP is 98422E103. A total of 105 filers reported holding XERIS BIOPHARMA HOLDINGS INC in Q2 2023. The put-call ratio across all filers is 0.13 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $23,332 | -29.0% | 12,544 | 0.0% | 0.01% | -31.2% |
| Q2 2023 | $32,865 | +60.7% | 12,544 | 0.0% | 0.02% | +45.5% |
| Q1 2023 | $20,447 | +22.6% | 12,544 | 0.0% | 0.01% | +10.0% |
| Q4 2022 | $16,684 | -16.6% | 12,544 | 0.0% | 0.01% | -23.1% |
| Q3 2022 | $20,000 | +5.3% | 12,544 | 0.0% | 0.01% | +8.3% |
| Q2 2022 | $19,000 | -48.6% | 12,544 | 0.0% | 0.01% | -36.8% |
| Q4 2021 | $37,000 | – | 12,544 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CAXTON CORP | 5,641,920 | $10,493,971 | 39.87% |
| Stonepine Capital Management, LLC | 5,915,372 | $11,002,592 | 3.66% |
| MPM BioImpact LLC | 3,987,967 | $7,417,619 | 1.98% |
| SINECERA CAPITAL, LLC | 253,101 | $470,768 | 0.63% |
| Opaleye Management Inc. | 390,000 | $725,400 | 0.24% |
| Alpine Global Management, LLC | 300,000 | $558,000 | 0.14% |
| DELTEC ASSET MANAGEMENT LLC | 315,246 | $586,358 | 0.13% |
| Redmile Group, LLC | 1,046,587 | $1,946,652 | 0.09% |
| GSA CAPITAL PARTNERS LLP | 381,231 | $709 | 0.06% |
| Soleus Capital Management, L.P. | 304,083 | $565,594 | 0.05% |